The Effects of 6β-Naltrexol, a Putative Neutral Opioid Antagonist, in Opioid-Dependent Subjects: A Proof-of-Concept Trial*Corresponding Author: John Mendelson MD, Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, United States, Tel: (415)-641-3370, Fax: (415)-641-3380, Email: [email protected]
Received Date: Jan 19, 2011 / Accepted Date: Apr 14, 2011 / Published Date: Apr 20, 2011
Citation: Mendelson J, Li L, Flower K, Harris W, Coyle JR, et al. (2011) The Effects of 6?-Naltrexol, a Putative Neutral Opioid Antagonist, in Opioid-Dependent Subjects: A Proof-of-Concept Trial. J Addict Res Ther 2:108.DOI: 10.4172/2155-6105.1000108
Copyright: © 2010 Mendelson J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Potential complications of prescription opioid use include abuse and constipation. 6β-Naltrexol (6βNTX), a neutral opioid antagonist, may alleviate these complications when co-formulated with μ-opioid analgesics. In a double-blind ascending dose study, four subjects on methadone maintenance received 6βNTX (0.05, 0.15, 0.50 and 1.0 mg). 6βNTX was generally well tolerated; three of four subjects reported willingness to take higher doses. Increased gastrointestinal activity was evidenced by decreased oral-cecal transit time and prompt laxation at higher doses.